semaglutide amenorrhea case report FOGSI 2026 Obesity Update- Part 1/5 Pharmacologic therapy is being considered earlier in the treatment pathway, reflecting the growing recognition of obesity as a metabolic and reproductive health condition. Key number: BMI Semaglutide (Ozempic) for Type 2

Additionally, 1.6 fewer BCCs per year were observed in patients being treated with this therapy

Novo Nordisk, the manufacturer of the brand names Ozempic, Wegovy, and Rybelsus, failed to disclose this unintendedbut dangerousside effect

Each prefilled pen contains 4 doses of 1 mg

In general, and similar to FDA-approved labeling for GLP-1 weight-management medications, you may be considered for a GLP-1 prescription if you: Have a BMI of 30 or higher (obesity), or Have a BMI between 2729.9 (overweight) plus a weight-related health condition Weight-related conditions can include high blood pressure, type 2 diabetes, sleep apnea, high cholesterol, or PCOS (Polycystic Ovary Syndrome), for example